ArticleNature communications2025
Catechol-based chemistry for hypoglycemia-responsive delivery of zinc-glucagon via hydrogel-based microneedle patch technology.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Transmetallic biomimetic Hydrogel implants restore osteogenesis-angiogenesis coupling via Fe/Co ionic microenvironment remodeling for enhancing osteoporotic fracture healing.Bioactive materials · 2027Article
- Advanced hydrogel-based drug delivery systems for psoriasis management: From material design to multi-target therapies.International journal of pharmaceutics: X · 2026Review
- Assembled Hyaluronic Acid Therapeutics for Targeting M1 Macrophages and Regulating Immune Homeostasis for Ulcerative Colitis Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Bioelectronic Considerations in Biomedical Microneedles.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Augmenting ultrasound for continuous glucose monitoring via a wearable acoustically readable microneedle patch.Science advances · 2026Article
- Sequential delivery of sinigrin and dabigatran by anMaterials today. Bio · 2026Article
- From conceptual design to translational progress: Emerging advances in intelligent microneedles for biomedical applications.Acta pharmaceutica Sinica. B · 2026Review
- Continuous insulin monitoring using an antibody-protecting zwitterionic microneedle patch.Nature biomedical engineering · 2026Article
- Engineering a Glucose-Responsive Glucagon Prodrug Through Arginine-Phenylboronic Acid Pendant Modification.Small science · 2026Article
- Barrier-disrupting microneedle technology: Overcoming physical, physiological, and pathological skin defenses to enhance therapeutic efficacy.Bioactive materials · 2026Review
- Evolution of 3D-Printed Microneedles toward Closed-Loop Theranostic Platforms.Research (Washington, D.C.) · 2026Review
- Impact of State of Ripeness and Culinary Treatments on the Hypoglycemic, Antioxidant, and Nutritional Properties of Two Varieties ofInternational journal of food science · 2026Article
- Environmental Mechanisms Influencing the Pathogenesis and Progression of Type 1 Diabetes.International journal of molecular sciences · 2025Review
- Microneedle-nanoparticle hybrid platforms for metabolic syndrome: advances in point-of-care diagnostics and transdermal therapeutics.Discover nano · 2025Review
- Microneedle-Based Multiplexed Monitoring of Diabetes Biomarkers: Capabilities Beyond Glucose Toward Closed-Loop Theranostic Systems.ACS sensors · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Hypoglycemia is a serious and potentially life-threatening condition for people with insulin-dependent diabetes. To provide a safeguard against hypoglycemia, we introduce a "smart" microneedle (MN) patch that senses glucose levels and delivers a blood glucose-raising agent (Zinc-Glucagon (Z-GCN)) in response to hypoglycemia. Herein, we describe the use of catechol and boronic acid chemistry to design a self-crosslinkable hydrogel-based MN that stimulates the release of Z-GCN during hypoglycemia. In this design, the catechol groups bind to Z-GCN through metal-ligand complexation. At hyperglycemia, boronic acids react with glucose to generate cyclic boronate esters. As the glucose concentration decreases, the boronic acid groups dissociate and are favored over Z-GCN in binding with catechol, which promotes the release of Z-GCN. We fully characterize the fabricated MN in vitro. Moreover, we further evaluate the MN and demonstrate the in vivo glucose-responsive delivery of Z-GCN from the patch. We also show its effectiveness in preventing hypoglycemia for up to 6 h in type 1 diabetic male rats against two consecutive insulin overdose challenges. Since many proteins/peptides have a high binding affinity to metal ions, the introduced mechanism driven by the competitive binding of catechol-metal ions has great implications in drug delivery applications of various protein/peptide-based therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.